|
|
||||||||
Vascular and Interventional Radiology |
1 From the Departments of Radiology (H.L.L., C.F.Y., H.B.P., C.K.H.C., P.H.L.), and Medicine (K.H.L., J.S.C., G.H.L.), Kaohsiung Veterans General Hospital, 386 Ta-Chung 1st Rd, Kaohsiung, Taiwan 813, and the Departments of Radiology (H.L.L., C.F.Y., H.B.P., C.K.H.C., P.H.L.) and Medicine (K.H.L., J.S.C., G.H.L.), National Yang-Ming University, Taipei, Taiwan. Received March 22, 1999; revision requested May 10; revision received June 21; accepted July 20. Address reprint requests to C.F.Y. (e-mail: cfyang@isca.vghks.gov.tw).
PURPOSE: To evaluate the safety and efficacy of single high-dose percutaneous acetic acid injection (PAI) for treatment of small (<3-cm-diameter) hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: Eighteen patients with HCC (22 nodules; diameter range, 1.53.0 cm) underwent single PAI. With ultrasonographic or computed tomographic (CT) guidance, 411 mL of 50% acetic acid was slowly injected into the center of the nodule through a skinny multiple-side-hole needle. Follow-up was performed with helical contrast materialenhanced CT. Complications of high-dose PAI were recorded.
RESULTS: Seventeen nodules showed no local recurrence (follow-up, 629 months) after single PAI. At a mean follow-up of 15.6 months, mean tumor diameter was 2.1 cm and mean injected volume was 6.4 mL. Four nodules showed residual tumor (mean tumor diameter, 2.6 cm; mean injected volume, 5.8 mL). The mean ratio of injected to estimated volume of acetic acid was 1.21 in cases of successful single PAI and 0.72 in cases of local recurrence (P < .001). One patient with preexistent right portal venous thrombosis died of hepatic failure 37 days after PAI. Other complications included severe pain (11%), high fever (4%), and segmental wedge infarction (4%).
CONCLUSION: Single high-dose PAI is safe and effective for treatment of small HCC.
Index terms: Acetic acid, 761.1264, 761.1269 Alcohol ablation, 761.1264, 761.1269 Liver, interventional procedures, 761.1264, 761.1269 Liver neoplasms, 761.323 Liver neoplasms, CT, 761.12113, 761.12115 Liver neoplasms, US, 761.12981, 761.12986
This article has been cited by other articles:
![]() |
S-M Lin, C-J Lin, C-C Lin, C-W Hsu, and Y-C Chen Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less Gut, August 1, 2005; 54(8): 1151 - 1156. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Arrive, O. Rosmorduc, H. Dahan, L. Fartoux, L. Monnier-Cholley, M. Lewin, R. Poupon, and J.-M. Tubiana Percutaneous Acetic Acid Injection for Hepatocellular Carcinoma: Using CT Fluoroscopy to Evaluate Distribution of Acetic Acid Mixed with an Iodinated Contrast Agent Am. J. Roentgenol., January 1, 2003; 180(1): 159 - 162. [Abstract] [Full Text] [PDF] |
||||